Abstract
Diarylmethylamines are key intermediates and products in the pharmaceutical industry. Herein we disclose a novel method toward the synthesis of these important compounds via C–H functionalization. Presented is a reversible deprotonation of N-Boc benzylalkylamines at the benzylic C–H with in situ arylation by a NiXant-Phos-based palladium catalyst (50–93% yield, 29 examples). The method is also successful with N-Boc-tetrahydroisoquinolines. The advantages of this method are it avoids strong bases, low temperatures, and the need to transmetallate to main group metals for the coupling.
Keywords: C–H functionalization, cross-coupling, diarylmethylamines, NiXantPhos ligand, pallladium
Diarylmethylamines are an important class of compounds that have had a significant impact in pharmaceutical sciences. For example, diarylmethylamines are core structures of Zyrtec,[1] Levocetirizine,[2] Meclizine,[3] and Solifenacin.[4] As such, their synthesis has attracted much attention. Generally, diarylmethylamines are prepared by nucleophilic addition of organometallic reagents to imines.[5] More recently, functionalization of sp3-hybridized C–H bonds adjacent to nitrogen has emerged as a powerful method for the formation of C–C bonds.[6]
Direct deprotonation and functionalization of the benzylic C–H bonds in secondary benzylamine derivatives under catalytic conditions is an attractive approach to elaborate amines, but remains challenging. The difficulty arises from the low acidity of sp3-hybridized benzylic C–H bonds adjacent to amino groups,[7] which usually require alkyl lithiums for deprotonation.[8] The resulting lithiated benzylic amines are quite versatile and can be captured with a variety of electrophiles.[8, 9] The strong bases used in these deprotonations, however, are incompatible with the vast majority of cross-coupling catalysts. To circumvent this incompatibility, Baudoin,[10] Knochel,[11] Campos,[12] and Dieter[13] have established two-step methods that commence with direct lithiation of secondary amines with strong bases, such as sBuLi, followed by in situ transmetallation to zinc, boron, or copper and subsequent coupling with aryl halides. The practicality of these approaches is diminished by the use of strong bases, low temperatures (–78°C), and the need to transmetallate to main group metals.
Our approach to arylation adjacent to amino groups focuses on reversible in situ C–H deprotonations of benzylic amines under catalytic conditions. To circumvent the low acidity of benzylic amine C–H groups, we initially employed (η6-C6H5-CH2NR2)Cr(CO)3 activation to decrease the pKa of benzylic C–H bonds (Scheme 1a).[14] The corresponding diarylmethylamines were obtained in excellent yields and enantioselectivities. To avoid the stoichiometric use of chromium, we employed a direct arylation of benzylic C(sp3)–H bonds using 2-azaallyl anions.[15] This strategy, introduced by Oshima and co-workers[16] and rendered synthetically useful by Buchwald’s group[17] and by us,[18] takes advantage of the stability of 2-azaallyl anions (Scheme 1b).
Scheme 1.
a) Synthesis of diarylmethylamines based on an η6-arene-activation strategy. b) Cross-coupling of N-benzyl benzophenone ketimines.
Considering the importance of diarylmethylamines in medicinal chemistry,[19] we envisioned a reversible deprotonation/functionalization of N-Boc benzylalkylamines at the benzylic C–H bonds under catalytic conditions. The Boc group is known to be useful in synthesis and was chosen for its ability to increase the acidity of the benzylic C–H bonds and to direct the base to facilitate deprotonation. Herein we report the first direct arylation of N-Boc-protected benzylalkylamines with aryl halides to provide N-Boc-diarylmethylamines (Scheme 2).
Scheme 2.
Palladium-catalyzed DCCP of N-Boc benzylalkylamines followed by deprotection.
Our general approach to deprotonative cross-coupling processes (DCCP) involves initial identification of a base for reversible deprotonation and an arylation catalyst that is compatible with the basic reaction conditions.[20] From our experience with DCCP of weakly acidic substrates (pKa 25–35), we chose van Leeuwen’s NiXantPhos ligand (Scheme 2) as a starting point.[21] We have recently demonstrated that NiXantPhos is deprotonated under basic reaction conditions, leading significantly enhanced catalyst reactivity.[21c] To identify a suitable base for the reversible deprotonation of the weakly acidic sp3-hybridized C–H bond adjacent to nitrogen, we screened six bases [LiN(-SiMe3)2, NaN(SiMe3)2, KN(SiMe3)2, LiOtBu, NaOtBu, and KOtBu] with the Pd(OAc)2/NiXantPhos system at 85°C in cyclopentylmethyl ether (CPME) for 24 h. As illustrated in Table 1, the bases leading to arylation products were MN(SiMe3)2 (M=Li, Na, K), affording 10–40% assay yields (AY, determined by 1H NMR spectroscopy of the crude products) of the diarylmethylamines in CPME (entries 1–3). None of the MOtBu (M=Li, Na, K) bases generated detectable amounts of arylated products (entries 4–6). Examination of four ethereal solvents [THF, DME, dioxane, and CPME] indicated that THF was an excellent choice (entry 9; 99% assay yield). To optimize the reaction conditions with the NiXantPhos/Pd(OAc)2 system, we examined different ratios of the benzylmethylamine pro-nucleophile, 4-bromotoluene, and LiN(SiMe3)2 at 50 and 85 °C. When 3 equiv of N-Boc benzylmethylamine (1a), 3 equiv of LiN(SiMe3)2 or NaN(SiMe3)2, and 1 equiv of 4-Tol-Br were used in THF, the desired arylated product was obtained in quantitative yield (entries 9 and 10). KN(SiMe3)2, on the other hand, gave the product 4a in only 21% yield (entry 11). Furthermore, decreasing the reaction temperature from 85 to 50 °C had a detrimental effect on the yield (20 %, entry 12).
Table 1.
Optimization of the DCCP of N-Boc benzylmethylamine with 4-bromotoluene.
![]() | ||||
---|---|---|---|---|
Entry | Base | 1a:2:3b | Solvent | Yield[a] [%] |
1 | LiN(SiMe3)2 | 3:3:1 | CPME | 40 |
2 | NaN(SiMe3)2 | 3:3:1 | CPME | 30 |
3 | KN(SiMe3)2 | 3:3:1 | CPME | 10 |
4 | LiOtBu | 3:3:1 | CPME | – |
5 | NaOtBu | 3:3:1 | CPME | – |
6 | KOtBu | 3:3:1 | CPME | – |
7 | LiN(SiMe3)2 | 3:3:1 | dioxane | 15 |
8 | LiN(SiMe3)2 | 3:3:1 | DME | 10 |
9 | LiN(SiMe3)2 | 3:3:1 | THF | 99 |
10 | NaN(SiMe3)2 | 3:3:1 | THF | 99 |
11 | KN(SiMe3)2 | 3:3:1 | THF | 21 |
12 | LiN(SiMe3)2 | 3:3:1 | THF | 20[b] |
13 | LiN(SiMe3)2 | 1:3:3 | THF | 61[c] |
14 | LiN(SiMe3)2 | 1:3:1 | THF | 74[d] |
15 | NaN(SiMe3)2 | 1:3:3 | THF | 57[e] |
16 | LiN(SiMe3)2 | 1.1:4:1 | THF | 99 (88)[f] |
Assay yield determined by 1H NMR analysis of unpurified reaction mixture with internal standard CH2Br2.
Reaction at 50°C.
30% unreacted 1a.
20% unreacted 1a.
18%, unreacted 1a.
Isolated yield.
Although the combination of Pd(OAc)2 and NiXant-Phos as precatalyst afforded the diarylmethylamine product 4a in excellent yield, the use of 3 equiv of N-Boc benzylmethylamine (entries9 and 10) required further attention. Reducing the equivalents of the benzylmethylamine pro-nucleophile from 3 to 1 equiv in THF at 85°C resulted in a drop in yield of 4a from >95 to 61% yield, along with 30% unreacted N-Boc benzylmethylamine 1a (entry 13). Changing base from LiN(SiMe3)2 to NaN(SiMe3)2 also resulted in a drop in yield of 4a to 57% (entry 15). The best result was obtained when 1.1 equiv of N-Boc benzylmethylamine, 1 equiv of 4-bromotoluene 3a, and 4 equiv of LiN(SiMe3)2 at 85°C were used in THF for 24 h, producing the product 4a in 99% AY and 88% isolated yield (entry 16).
With the optimized conditions (entry 16, Table 1), we sought to evaluate the substrate scope of the arylation of N-Boc benzylmethylamine (Table 2). Overall, the DCCP showed good to excellent reactivity with a variety of aryl electrophiles. For example, the arylated products were obtained in 50–91% yields for para, meta, and ortho alkyl-substituted aryl bromides, chlorides, an aryl iodide, and an aryl triflate (4a, 4c–4e, Table 2). Sterically hindered 2-bromotoluene proved to be a more challenging substrate, furnishing the product 4e in 50% yield. On the other hand, 1-bromonaphthalene resulted in 4 f in 78% yield. Aryl halides bearing 3-methoxy and 3-N,N-dimethylamino groups led to coupling products 4g and 4h in 64 and 93% yields, respectively. Electron-rich 4-bromo-and 4-chloroanisole yielded the coupling product 4i in 87 and 85% yield, respectively. The reactivity with 1-bromo-and 1-chloro-4-fluorobenzene was lower, giving 4j in 70 and 60% yield, respectively. Acetals are known to undergo C–O bond cleavage with reactive organometallic reagents,[22] however, the C–H functionalization product 4k was isolated in 68% yield. With heterocyclic 4-chlorophenyl pyrrole, the arylated product 4l was obtained in 93% yield. N-TBS 5-bromoindole furnished the heterocyclic product 4m in 50% yield.
Table 2.
Cross-coupling of N-Boc benzylmethylamine with aryl electrophiles.[a]
See the Supporting Information for experimental details.
We next turned our attention to the scope of N-Boc benzylmethylamine derivatives (Table 3). Heterocyclic N-Boc methyl(-pyridin-3-methyl)amine exhibited good reactivity with alkylsubstituted, electron-donating and electron-deficient aryl bromides (4n–4p, 72–98% yield). The benzylmethylamine bearing a 3-OMe substituent furnished the desired products in 57–90% yield (4g, 4q, and 4r). The tert-butyl methyl(naphthalen-1-ylmethyl) carbamate also afforded products in 57–80% yield (4s, 4t, and 4u). N-Boc 4-fluorobenzylmethylamine coupled with bromobenzene and 4-bromoanisole in 76 and 73% yields (4j and 4v), respectively. When the methyl group on N-Boc benzylmethylamine was changed to N-ethyl group, the arylated products with 4-bromotoluene and 4-bromoanisole were obtained in 75 and 60% yield, respectively (4w and 4x).
Table 3.
Cross-coupling of N-Boc benzylalkylamines with aryl bromides.[a]
See the Supporting Information for experimental details.
10/20 mol% of Pd(OAc)2 and NiXantPhos used.
Unfortunately, reactions with 2-thiophenyl, 2-furyl, 2- and 4-pyridyl-derived benzylmethylamines did not yield any detectable amounts of coupling products under these conditions. These substrates are significantly more acidic than N-Boc benzylmethylamine and will require different conditions to form the desired products.
The Boc-protected 4c was treated with hydrochloric acid followed by basic work up to provide the secondary amine 5c in 75% yield (Scheme 3).
Scheme 3.
Deprotection of the Boc group to provide 5c from 4c.
We next desired to expand our method to the synthesis of 1-phenyl-1,2,3,4-tetrahydroisoquinoline (5aa, Scheme 4), a key intermediate in the antimuscarinic agent Solifenacin (Vesicare).[23] 1-Arylated tetrahydroisoquinolines have also been studied for their anti-HIV activities.[24]
Scheme 4.
Cross-coupling of N-Boc tetrahydroisoquinoline 1aa, and deprotection to give 1-phenyl tetrahydroisoquinoline 5aa, a key intermediate for Solifenacin (6).
Under our DCCP conditions, the cross-coupling of 1aa took place smoothly to provide 4aa in 81% isolated yield (Scheme 4). The arylated tetrahydroisoquinoline products derived from 4-bromoanisole and 1-bromo-4-fluorobenzene were obtained in 76 and 65% yields, respectively (4ab and 4ac, Scheme 4). Toward the synthesis of the key intermediate (5aa), the arylated product (4aa) was deprotected with HCl followed by basic workup to provide 1-phenyl-1,2,3,4-tetrahydroisoquinoline 5aa in 95% yield. Racemic 5aa has been used in the synthesis of Solifenacin (6, Scheme 4).[25]
In summary, we have developed the first direct α-arylation of N-Boc benzylalkylamines with aryl electrophiles by using deprotonative cross-coupling processes. This method avoids two-step procedures involving low temperature deprotonation with very strong bases and transmetallation to main group intermediates previously used. Key to success of this approach are the development of conditions for the reversible in situ C– H deprotonation of the substrates and the application of a Pd(NiXantPhos)-based catalyst that enables the arylation to be conducted under mild conditions.
Supplementary Material
Acknowledgments
P.J.W acknowledges the NIH (National Institute of General Medical Sciences GM 104349) and the NSF (CHE-1152488).
Footnotes
Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/chem.201502017.
References
- 1.Li JJ, Johnson DS, Sliskovic DR, Roth B. Contemporary Drug Synthesis. Wiley-Interscience; 2004. [Google Scholar]
- 2.Grant JA, Riethuisen J-M, Moulaert B, DeVos C. Ann. Allergy Asthma Immunol. 2002;88:190–197. doi: 10.1016/S1081-1206(10)61995-3. [DOI] [PubMed] [Google Scholar]
- 3.Fuhrhop J-H, Li G. Organic Synthesis: Concepts and Methods. 3rd. Wiley; 2003. p. 237. [Google Scholar]
- 4.Ko Y, Malone DC, Armstrong EP. Pharmacotherapy. 2006;26:1694–1702. doi: 10.1592/phco.26.12.1694. [DOI] [PubMed] [Google Scholar]
- 5.a) Silverio DL, Torker S, Pilyugina T, Vieira EM, Snapper ML, Haeffner F, Hoveyda AH. Nature. 2013;494:216–221. doi: 10.1038/nature11844. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Xu H-C, Chowdhury S, Ellman JA. Nat. Protoc. 2013;8:2271–2280. doi: 10.1038/nprot.2013.134. [DOI] [PubMed] [Google Scholar]; c) Kobayashi S, Mori Y, Fossey JS, Salter MM. Chem. Rev. 2011;111:2626–2704. doi: 10.1021/cr100204f. [DOI] [PubMed] [Google Scholar]; d) Zuend SJ, Coughlin MP, Lalonde MP, Jacobsen EN. Nature. 2009;461:968–970. doi: 10.1038/nature08484. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Yamada K-i, Tomioka K. Chem. Rev. 2008;108:2874–2886. doi: 10.1021/cr078370u. [DOI] [PubMed] [Google Scholar]
- 6.a) Li Z, Li C-J. J. Am. Chem. Soc. 2005;127:6968–6969. doi: 10.1021/ja0516054. [DOI] [PubMed] [Google Scholar]; b) Li Z, Li C-J. Org. Lett. 2004;6:4997–4999. doi: 10.1021/ol047814v. [DOI] [PubMed] [Google Scholar]; c) Li Z, Li C-J. J. Am. Chem. Soc. 2004;126:11810–11811. doi: 10.1021/ja0460763. [DOI] [PubMed] [Google Scholar]
- 7.a) Beak P, Basu A, Gallagher DJ, Park YS, Thayumanavan S. Acc. Chem. Res. 1996;29:552–560. [Google Scholar]; b) Meyers AI. Aldrichimica Acta. 1985;18:59–68. [Google Scholar]
- 8.a) Schlosser M, Limat D. J. Am. Chem. Soc. 1995;117:12342–12343. [Google Scholar]; b) Resek JE, Beak P. J. Am. Chem. Soc. 1994;116:405–406. [Google Scholar]
- 9.a) Clayden J, Dufour J, Grainger DM, Helliwell M. J. Am. Chem. Soc. 2007;129:7488–7489. doi: 10.1021/ja071523a. [DOI] [PubMed] [Google Scholar]; b) Fernández I, González J, López-Ortiz F. J. Am. Chem. Soc. 2004;126:12551–12564. doi: 10.1021/ja039863t. [DOI] [PubMed] [Google Scholar]; c) Faibish NC, Park YS, Lee S, Beak P. J. Am. Chem. Soc. 1997;119:11561–11570. [Google Scholar]
- 10.Millet A, Dailler D, Larini P, Baudoin O. Angew. Chem. Int. Ed. 2014;53:2678–2682. doi: 10.1002/anie.201310904. Angew. Chem. 2014, 126, 2716–2720. [DOI] [PubMed] [Google Scholar]
- 11.Seel S, Thaler T, Takatsu K, Zhang C, Zipse H, Straub BF, Mayer P, Knochel P. J. Am. Chem. Soc. 2011;133:4774–4777. doi: 10.1021/ja201008e. [DOI] [PubMed] [Google Scholar]
- 12.Campos KR, Klapars A, Waldman JH, Dormer PG, Chen C-y. J. Am. Chem. Soc. 2006;128:3538–3539. doi: 10.1021/ja0605265. [DOI] [PubMed] [Google Scholar]
- 13.Dieter RK, Li SJ. J. Org. Chem. 1997;62:7726–7735. [Google Scholar]
- 14.a) McGrew GI, Stanciu C, Zhang J, Carroll PJ, Dreher SD, Walsh PJ. Angew. Chem. Int. Ed. 2012;51:11510–11513. doi: 10.1002/anie.201201874. Angew. Chem. 2012, 124, 11678–11681. [DOI] [PubMed] [Google Scholar]; b) McGrew GI, Temaismithi J, Carroll PJ, Walsh PJ. Angew. Chem. Int. Ed. 2010;49:5541–5544. doi: 10.1002/anie.201000957. Angew. Chem. 2010, 122, 5673–5676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.a) Li Z, Jiang Y-Y, Yeagley AA, Bour JP, Liu L, Chruma JJ, Fu Y. Chem. Eur. J. 2012;18:14527–14538. doi: 10.1002/chem.201201425. [DOI] [PubMed] [Google Scholar]; b) Weaver JD, Recio IIIA, Grenning AJ, Tunge JA. Chem. Rev. 2011;111:1846–1913. doi: 10.1021/cr1002744. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Grenning AJ, Tunge JA. J. Am. Chem. Soc. 2011;133:14785–14794. doi: 10.1021/ja205717f. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Fields WH, Chruma JJ. Org. Lett. 2010;12:316–319. doi: 10.1021/ol902651j. [DOI] [PubMed] [Google Scholar]; e) Yeagley AA, Lowder MA, Chruma JJ. Org. Lett. 2009;11:4022–4025. doi: 10.1021/ol901745x. [DOI] [PubMed] [Google Scholar]; f) Fields WH, Khan AK, Sabat M, Chruma JJ. Org. Lett. 2008;10:5131–5134. doi: 10.1021/ol801986m. [DOI] [PubMed] [Google Scholar]; g) Yeagley AA, Chruma JJ. Org. Lett. 2007;9:2879–2882. doi: 10.1021/ol071080f. [DOI] [PubMed] [Google Scholar]; h) Burger EC, Tunge JA. J. Am. Chem. Soc. 2006;128:10002–10003. doi: 10.1021/ja063115x. [DOI] [PubMed] [Google Scholar]; i) Tunge JA, Burger EC. Eur. J. Org. Chem. 2005;2005:1715–1726. [Google Scholar]
- 16.a) Niwa T, Suehiro T, Yorimitsu H, Oshima K. Tetrahedron. 2009;65:5125–5131. [Google Scholar]; b) Niwa T, Yorimitsu H, Oshima K. Org. Lett. 2008;10:4689–4691. doi: 10.1021/ol802070d. [DOI] [PubMed] [Google Scholar]
- 17.Zhu Y, Buchwald SL. J. Am. Chem. Soc. 2014;136:4500–4503. doi: 10.1021/ja501560x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.a) Li M, Yücel B, Adrio J, Bellomo A, Walsh PJ. Chem. Sci. 2014;5:2383–2391. doi: 10.1039/C3SC53526F. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Li M, Berritt S, Walsh PJ. Org. Lett. 2014;16:4312–4315. doi: 10.1021/ol502043j. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ameen D, Snape TJ. Med. Chem. Commun. 2013;4:893–907. [Google Scholar]
- 20.a) Gao F, Kim B-S, Walsh PJ. Chem. Commun. 2014;50:10661–10664. doi: 10.1039/c4cc05307a. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Montel S, Jia T, Walsh PJ. Org. Lett. 2014;16:130–133. doi: 10.1021/ol403124g. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Frensch G, Hussain N, Marques FA, Walsh PJ. Adv. Synth. Catal. 2014;356:2517–2524. doi: 10.1002/adsc.201400679. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Hussain N, Frensch G, Zhang J, Walsh PJ. Angew. Chem. Int. Ed. 2014;53:3693–3697. doi: 10.1002/anie.201309084. Angew. Chem. 2014, 126, 3767–3771. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Zheng B, Jia T, Walsh PJ. Org. Lett. 2013;15:1690–1693. doi: 10.1021/ol400472v. [DOI] [PubMed] [Google Scholar]; f) Zhang J, Bellomo A, Creamer AD, Dreher SD, Walsh PJ. J. Am. Chem. Soc. 2012;134:13765–13772. doi: 10.1021/ja3047816. [DOI] [PubMed] [Google Scholar]
- 21.a) van der Veen LA, Keeven PH, Schoemaker GC, Reek JNH, Kamer PCJ, van Leeuwen PWNM, Lutz M, Spek AL. Organometallics. 2000;19:872–883. [Google Scholar]; b) Kamer PCJ, van Leeuwen PWNM, Reek JNH. Acc. Chem. Res. 2001;34:895–904. doi: 10.1021/ar000060+. [DOI] [PubMed] [Google Scholar]; c) Zhang J, Bellomo A, Trongsiriwat N, Jia T, Carroll PJ, Dreher SD, Tudge MT, Yin H, Robinson JR, Schelter EJ, Walsh PJ. J. Am. Chem. Soc. 2014;136:6276–6287. doi: 10.1021/ja411855d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Müller P, Nury P, Bernardinelli G. Eur. J. Org. Chem. 2001:4137–4147. [Google Scholar]
- 23.Bolchi C, Pallavicini M, Fumagalli L, Straniero V, Valoti E. Org. Process Res. Dev. 2013;17:432–437. [Google Scholar]
- 24.Chen K-x, Xie H-y, Li Z-g, Gao J-r. Bioorg. Med. Chem. Lett. 2008;18:5381–5386. doi: 10.1016/j.bmcl.2008.09.056. [DOI] [PubMed] [Google Scholar]
- 25.a) Ye Z-S, Guo R-N, Cai X-F, Chen M-W, Shi L, Zhou Y-G. Angew. Chem. Int. Ed. 2013;52:3685–3689. doi: 10.1002/anie.201208300. Angew. Chem. 2013, 125, 3773–3777. [DOI] [PubMed] [Google Scholar]; b) Niphade NC, Jagtap KM, Mali AC, Solanki PV, Jachak MN, Mathad VT. Monatsh. Chem. 2011;142:1181–1186. [Google Scholar]; c) Naito R, Yonetoku Y, Okamoto Y, Toyoshima A, Ikeda K, Takeuchi M. J. Med. Chem. 2005;48:6597–6606. doi: 10.1021/jm050099q. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.